FDA — authorised 26 February 2004
- Application: BLA125085
- Marketing authorisation holder: GENENTECH
- Local brand name: AVASTIN
- Indication: VIAL — INTRAVENOUS
- Status: approved
🇺🇸 carboplatin paclitaxel bevacizumab in United States
FDA authorised carboplatin paclitaxel bevacizumab on 26 February 2004
Marketing authorisation
Other Oncology approved in United States
Frequently asked questions
Is carboplatin paclitaxel bevacizumab approved in United States?
Yes. FDA authorised it on 26 February 2004.
Who is the marketing authorisation holder for carboplatin paclitaxel bevacizumab in United States?
GENENTECH holds the US marketing authorisation.